Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Innovent’s Adalimumab And Bevacizumab Get New Indications In China

New Indications Include Treatment of Psoriasis, Uveitis And Glioblastoma

Executive Summary

Chinese biotech specialist Innovent Biologics has received approval for new indications for its adalimumab and bevacizumab biosimilars from China’s NMPA. 

You may also be interested in...



Innovent And Etana Get Indonesian Bevacizumab Nod

Innovent and marketing partner Etana have celebrated an approval for their Bevagen bevacizumab biosimilar from the Indonesian regulator.

Shanghai Junshi Announces Chinese Adalimumab Approval

Shanghai Junshi and Mabwell have received approval from China’s NMPA for their co-developed adalimumab biosimilar rival to Humira.

Innovent Expands Internationally With Indonesia Deal

Innovent Biologics has broadened its international reach by striking a licensing deal with PT Etana Biotechnologies in Indonesia for its Byvasda bevacizumab biosimilar.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB150551

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel